CHINA DRUG INSPECTION
Shizhentang Badong Pharmaceutical Co., Ltd.China NMPA Drug Inspection - Shizhentang Badong Pharmaceutical Co., Ltd. - Mulberry
China NMPA drug inspection for Shizhentang Badong Pharmaceutical Co., Ltd. published March 25, 2020. Drug: Mulberry.
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
Record Summary
China NMPA drug inspection for Shizhentang Badong Pharmaceutical Co., Ltd. published March 25, 2020. Drug: Mulberry.
Get More Insights
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
1.5M+ regulatory data points
Real-time compliance monitoring
Interactive analytics dashboard
Looking for more records? Our platform provides access to thousands of similar regulatory documents with advanced search and filtering capabilities.
Record Information
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox